ABSTRACT: A formaldehyde-mediated aggregation pathway (FMAP) has been shown to be primarily responsible for the solid-state aggregation of lyophilized formalinized protein antigens [e.g., tetanus toxoid (TT) and formalinized bovine serum albumin (f-BSA)] in the presence of moisture and physiological temperature. Coincorporation of the formaldehyde-interacting amino acid, histidine, strongly inhibits the FMAP. The purpose of this study was to test whether previous solid-state data are applicable toward the stabilization of formalinized antigens encapsulated in poly(lactide-co-glycolide) (PLGA)-based microspheres. Formaldehyde-treated bovine serum albumin (f-BSA) and BSA were selected as a model formalinized protein antigen and a nonformalinized control, respectively. As in the solid state, we found that the FMAP was dominant in the aggregation of f-BSA encapsulated in PLGA 50/50 microspheres, whereas the aggregation mechanism of encapsulated BSA was mostly converted from thiol±disul®de interchange to an acid-catalyzed noncovalent pathway. The lack of noncovalent aggregation in encapsulated f-BSA could be explained by its higher thermodynamic stability after formalinization, which inhibits protein unfolding. Targeting the FMAP, coencapsulation of histidine and trehalose successfully inhibited the aggregation of f-BSA in microspheres. By combining the use of an optimized oil-in-oil (o/o) encapsulation method, coencapsulation of histidine and trehalose, and use of low-acid-content poly(D,L-lactide) (PLA) and poly(ethylene glycol) (PEG) blends, a 2-month continuous release of f-BSA was achieved with the absence of aggregation. ß
INTRODUCTION
Poly(lactide-co-glycolide) (PLGA) microspheres have shown great potential as carriers for singledose vaccine delivery and the advantages of PLGA microspheres are well known. 1±3 A major obstacle in developing this delivery system is the instability of encapsulated protein antigens during exposure to physiological conditions (i.e., elevated humidity and temperature). Protein antigens may undergo hydrolysis, oxidation, deamidation, and aggregation in polymer devices, resulting in the loss of antigenicity or incomplete release of active antigens. 1, 4 For example, in the development of controlled-release tetanus toxoid (TT) microspheres, the incomplete release and antigenicity losses of TT were attributed to the aggregation and acid-induced denaturation of the antigen inside microspheres. 5, 6 The stability of protein antigens in PLGA systems is rather complicated. It is not only related to the physical and chemical properties of antigens but also affected by the physical and chemical processes during microsphere preparation, storage, and in vivo antigen release. 1 In addition to characteristics determined by their original primary and higher order structures, some protein antigens may acquire additional properties from their preparation procedures, which may cause some additional instability problems. For example, formaldehyde treatment has been commonly used to convert toxins into relatively inert but still antigenic toxoids. Formaldehyde-treated antigens, [e.g., TT, formalinized bovine serum albumin (f-BSA), and formalinized ribonuclease A (f-RNase)] have been shown to possess special reactive species that trigger a unique formaldehyde-mediated aggregation at intermediate moisture levels. 7, 8 Brie¯y, labile antigen±formaldehyde linkages formed during formaldehyde treatment are converted to highly reactive electrophiles (e.g., Schiff bases) under appropriate conditions. When lyophilized antigens are incubated at elevated humidity and temperature, Schiff bases may combine with nucleophiles within the same or different protein molecules to form intra-and intermolecular crosslinks, eventually leading to the formation of nondisul®de-linked covalently bonded insoluble aggregates. We term this unique process the formaldehyde-mediated aggregation pathway (FMAP). Our previous work demonstrated coincorporation of strongly formaldehyde-interacting amino acids (e.g., histidine) as well as prior reduction of f-BSA with cyanoborohydride can signi®cantly inhibit the FMAP. 8 Formalinized protein antigens represent a large family of vaccine antigens. The formalinized antigens, TT and diphtheria toxoid (DT), are two top priority antigens of the World Health Organization for the development of single-dose vaccine formulations. 9 For more than a decade, research efforts have intensi®ed toward the formulation design of a controlled-release TT vaccine. However, no ideal continuous release of antigenic TT has been achieved, largely because of the antigen instability in polymeric systems. Many excipients aimed at improving the microsphere microclimate (e.g., BSA, Poloxamer 188, and basic salts) have been coencapsulated with TT to improve antigen stability. 10, 11 Various kinds of stabilizers (e.g., heparin, dextran, and trehalose) have also been tested for their capacity to maintain the antigenicity of TT after lyophilization. 12 However, few studies have considered the in¯uence of formalinization on the stability of TT in PLGA systems. 13 It is unclear if formaldehyde-mediated aggregation processes will occur after antigens are encapsulated in PLGA microspheres. Since the FMAP is general to any formaldehyde-treated protein antigen, the answer to this question may be bene®cial to such antigens undergoing single-dose vaccine development.
The objective of this study was to investigate the stability of encapsulated formalinized antigens and to answer the question whether the FMAP occurs in PLGA microspheres. Moreover, if the FMAP is dominant, corresponding stabilization strategies will be developed against the FMAP in PLGA microspheres. The ®nal goal of this study is to achieve continuous release of formalinized antigen from microspheres with the absence of aggregation. As in our previous study, f-BSA was used as a model antigen to be encapsulated in PLGA microspheres for the stability investigation. To delineate formaldehyde-mediated aggregation, BSA was employed as a nonformalinized control. 8 
EXPERIMENTAL SECTION Materials
Poly(D,L-lactide-co-glycolide) (PLGA) 50/50 with inherent viscosity (iv) of 0.20 and 0.64 dL/g in hexa¯uoroisopropanol and poly(D,L-lactide) (PLA) with iv of 1.07 dL/g in CHCl 3 were from BPI (Birmingham, AL). Bovine serum albumin (BSA; A-3059, Lot 32H0463) was purchased from Sigma Chemical Company (St. Louis, MO). Formalinized bovine serum albumin (f-BSA) was developed in our lab by treating BSA with formaldehyde for 3 weeks. 8 All other biochemicals and chemicals were of analytical grade or purer and obtained from commercial suppliers.
Microencapsulation
The polymeric microspheres were prepared by either a water-in-oil-in-water double emulsion± solvent evaporation (w/o/w) method or an oil-in-oil single emulsion±solvent extraction (o/o) method. In the w/o/w method, an aqueous solution of antigen in 1 mM pH 7.3 phosphate buffer was emulsi®ed into a methylene chloride±PLGA 50/50 solution by homogenization. Then 1% poly(vinyl alcohol) (PVA) aqueous solution was added to the ®rst w/o emulsion and the second w/o/w emulsion was formed by vortex at high speed.
This emulsion was poured into a hardening aqueous bath containing 0.3% PVA and stirred for 3 h at room temperature and atmospheric pressure. The hardened microspheres were collected by centrifugation, washed with double distilled water, and lyophilized over 2 days. In the anhydrous o/o method, dried protein powders were directly suspended in acetonitrile±polymer solution. The lyophilization protocol to prepare the dried protein powder was as follows: protein aqueous solutions in 1 mM pH 7.3 phosphate buffer were¯ash frozen in liquid N 2 and placed on a Labconco Freeze Dryer (Kansas City, MO) operating at 30 mm of Hg pressure and a condenser temperature of À468C. Typically, protein samples were removed after 48 h. Then, a uniform suspension of sieved antigen powder (`45 mm) in acetonitrile±polymer solution was homogenized at 15,000 rpm in an ice bath. The antigen suspension was added in a dropwise manner into the continuous phase [cottonseed oil containing 1.6% (w/v) span 85] stirred at 750 rpm with an overhead stirrer. After 5 h, petroleum ether (bp, 50±1108C) was poured into the cottonseed oil bath to extract the acetonitrile from the polymer. After an additional 15 min of stirring, the microspheres were ®ltered, washed with 250 mL of petroleum ether and lyophilized.
Scanning Electron Microscopy (SEM) of Microspheres
The microspheres were coated with gold-palladium by using Pelco model 3 sputter coater 91000. Surface morphology of the microspheres was examined by a Philips XL Scanning Electron Microscope.
Determination of Antigen Loading in Microspheres
The amount of antigen encapsulated in microspheres was determined by recovering the protein directly from the microspheres. First, acetone was added in microspheres to dissolve the polymer. The mixture was vortexed and centrifuged and then supernatant was removed. After the removal of polymer was repeated three times, the remaining protein pellet was reconstituted in PBS containing 0.02% Tween 80 1 (PBST) and protein content was determined by the Coomassie Plus method (Pierce Chem Co., Rockford, IL). Encapsulation ef®ciency for the w/o/w method was between 49 and 90% and for the o/o method between 90 and 100%.
Evaluation of Model Antigen Aggregation in Microspheres Exposed to a Humid Environment
Ten milligrams of microspheres were incubated at 378C and 80 or 97% relative humidity (RH). Saturated (NH 4 ) 2 SO 4 and K 2 SO 4 aqueous solutions placed in glass dessicators were used to attain 80 and 97% RH, respectively.
14 Microspheres were collected periodically, and the soluble protein content in microspheres was determined as described in Determination of Antigen Loading in Microspheres. Any insoluble protein aggregates were collected by centrifugation and reconstituted in denaturing agent [8 M urea or 6 M guanidineÁHCl (GnCl)]. Determination of any aggregates soluble in denaturing agent gave the amount of noncovalently bonded aggregates. With the further addition of reducing agent (10 mM DTT 1 mM EDTA), any disul®de-bonded aggregates were dissolved. The total dissolved portion in denaturing and reducing agents gave the total amount of noncovalent and disul®de-bonded aggregates. Any remaining aggregates undissolved in combined denaturing and reducing agents were considered as formaldehyde-mediated aggregates. 8 
Evaluation of Antigen Release From Microspheres
Samples of microspheres (20 mg) were suspended in 1 mL of PBST. The suspension was incubated at 378C with mild agitation. At preselected intervals, release media were removed for protein assay and replaced with fresh buffer. The amount of protein released was assayed by the Coomassie Plus method. At the end of release, the protein remaining in the polymer was determined as discussed in the next section.
Evaluation of Antigen Aggregation in Microspheres During Release
Microspheres were incubated in PBST at 378C. At predetermined time intervals, the release medium was removed for determination of protein content, and microspheres were collected and dried. The remaining protein in the polymer was analyzed as described in Evaluation of Model Antigen Aggregation in Microspheres Exposed to a Humid Environment.
Chemical Denaturation of Model Antigens by GnCl 15
For GnCl unfolding of BSA and f-BSA, 100 mg/mL of protein stock solution and 8 M GnCl were prepared in 30 mM MOPS buffer (pH 7.0). Protein stock solution was diluted in various concentrations of GnCl to reach the ®nal protein concentration of 6.25 mg/mL. The¯uorescence of model antigens at 345 nm was determined when the protein was excited at 280 nm by using a Fluromax-2¯urometer (Instrument S. A., Inc., Edison, NJ). The C m parameter, the GnCl concentration at which the unfolded fraction of protein is 0.5, was determined from the unfolding curve (unfolding fraction plotted against GnCl concentration). Unfolding fraction can be calculated by the following equation:
where a is the unfolded fraction of the protein; F N and F U are the¯uorescence of the native (in absence of GnCl) and fully unfolded states (in concentrated GnCl), respectively; and F i is the protein¯uorescence at the ith concentration of GnCl.
RESULTS AND DISCUSSION Aggregation Kinetics of Model Antigens in PLGA
To test the stability of encapsulated f-BSA, we ®rst encapsulated the antigen in PLGA 50/50 (iv 0.20 dL/g) by the most commonly used w/o/w method. To distinguish between the FMAP and typical aggregation pathways, we also encapsulated BSA as a control. Protein loading in both formulations was 1.5%. BSA and f-BSA microspheres were incubated in PBST at 378C. The release of protein antigens and the loss of soluble antigens due to aggregation in the microspheres were monitored simultaneously. As seen in Figure 1A , incomplete release of BSA and f-BSA ($30% of antigens) was observed. In the polymer, a slow growth of insoluble aggregates of both BSA and f-BSA appeared ( Figure 1B) . By 28 days, $40% of initially encapsulated BSA had become insoluble and unreleasable from the polymer. Insoluble f-BSA inside microspheres increased from 8 to 31% after 7 and 28 days of incubation.
To evaluate the stability of encapsulated antigens in the moist polymer, microspheres were incubated at 80% RH and 378C. Protein release was presumably prevented under these conditions. As seen in Figure 2 , a growing amount of insoluble aggregates were observed in both BSA and f-BSA microspheres. However, f-BSA had much faster aggregation kinetics. By 7 days, only 6.9 % of f-BSA remained soluble in microspheres, whereas BSA lost $80% of soluble protein in microspheres after 28 days of incubation.
Therefore, each antigen, BSA and f-BSA, slowly formed aggregates inside microspheres both during release and when incubated at elevated humidity.
Aggregation of f-BSA Encapsulated in PLGA via the FMAP
The aggregates formed in PLGA microspheres during the previous deleterious conditions (release and humidity) were solublized in denaturing and reducing solvents to elucidate the aggregation pathway for each antigen ( Table 1) . As reported in the solid state, 8 virtually none (`11%) of the aggregates formed from encapsulated f-BSA in PLGA microspheres were soluble in combined denaturing and reducing agents (8 M urea 10 mM DTT 1 mM EDTA), after f-BSAcontaining microspheres were incubated in either the release medium or the humid condition (80% RH) for 28 days. Therefore, this insolubility of f-BSA aggregates demonstrates that the FMAP does occur for f-BSA in microspheres.
In contrast, aggregates formed from the encapsulated control antigen, BSA, were always soluble in the combined reducing and denaturing solvents irrespective of condition used, although the distribution of noncovalent to disul®de-bonded aggregation for BSA was altered depending on the deleterious conditions (Table 1) . For example, after 28 days of release, 76% of BSA aggregates formed in the polymer were soluble in denaturing agents (8 M urea) , indicating that the noncovalent aggregates had formed, whereas remaining aggregates were completely soluble in the combined denaturing and reducing agents (8 M urea 10 mM DTT 1 mM EDTA), indicating the minor involvement of thiol±disul®de interchange. For BSA microspheres incubated at 378C and 80% RH, the same type of water-insoluble aggregates were observed among the remaining BSA (Table 1) , except a higher number of disul®de-bonded aggregates were observed. Thus, examination of the aggregation behavior of the nonformalinized antigen con®rms that f-BSA underwent a different aggregation pathway from BSA in PLGA microspheres.
Comparing the stability of encapsulated antigens during release with that under humid conditions, aggregation was more extensive in the latter case. This increased aggregation was possibly because the antigen release from microspheres was inhibited during humidity exposure, thereby increasing the residence time of antigens in the polymer and the probability of aggregation. When incubated at elevated humidity and 378C, as in the release medium, PLGA degradation still occurs, because of uptake of water vapor at 378C, and a similar deleterious microenvironment will be produced, although at a different rate. In both cases, encapsulated protein antigens will be continuously exposed to elevated moisture levels, polymer hydrophobic surfaces, and an acidic pH because of the accumulation of acidic polymer degradation products. 17 Our data suggest that the difference in incubation conditions was not great enough to alter the aggregation mechanisms corresponding to either of the model antigens. Therefore, the humidity condition can be a relatively simpler but useful model system to study the antigen aggregation mechanism, as shown previously. 18 In addition, by using humidity studies, stabilization strategies may be analyzed mechanistically and stabilizers can be identi®ed more ef®ciently. Antigen stability data obtained from humidity experiments will also provide important information with respect to microsphere storage conditions.
Comparison of Protein Aggregation in the Nonencapsulated Solid-State and in PLGA
When compared with aggregation of nonencapsulated antigens in the solid state, the aggregation mechanism of encapsulated BSA and f-BSA showed different changes. As seen in Table 1 , nonencapsulated BSA formed aggregates almost exclusively via the thiol±disul®de interchange aggregation pathway, evidenced by 92% aggregates soluble in combined denaturing and reducing agents, but no aggregates soluble in denaturing agent alone. In contrast, encapsulated BSA aggregates were mostly noncovalent and partially disul®de-bonded. For f-BSA, the FMAP dominated in both nonencapsulated and encapsulated f-BSA samples.
Different from its nonencapsulated counterparts, encapsulated protein antigens were continuously exposed to the deleterious microsphere microclimate. How does the deleterious microclimate suppress the thiol±disul®de interchange initiated by a single free thiol group in BSA, but promote the noncovalent interaction between BSA molecules? Previous work in our lab has demonstrated that it is the acidic microclimate and intermediate moisture levels in microspheres that cause noncovalent aggregation of BSA. 18, 19 BSA is known to undergo a conformational transition from the F (fast) to E (expanded) isoforms at pH 2.7. In the E form, more hydrophobic area is exposed, which provides the driving force for noncovalent aggregation via hydrophobic interactions. In addition to the conformational change, the nucleophilic free thiolate becomes protonated due to the acidic pH in microspheres, contributing to the conversion of the BSA aggregation mechanism.
f-BSA has a secondary and tertiary structure similar to that of BSA. 8 Why did the acidic polymer microclimate not change the f-BSA aggregation behavior signi®cantly? From the kinetic point of view, formaldehyde-mediated aggregation is so fast (b 90% of f-BSA became insoluble within 1 week) that the acidic microclimate may have had insuf®cient time to build up. Thus, a reduced effect of the acidic microclimate on the aggregation of f-BSA is expected. In addition, after formaldehyde treatment, formaldehyde linkages within f-BSA molecule are expected to rigidify its structure; thus, f-BSA may be conformationally more stable and less unlikely to unfold at the acidic microclimate. We con®rmed this hypothesis by performing a GnCl denaturation curve on BSA and f-BSA. As seen in Figure 3 , f-BSA has a much higher C m (the GnCl concentration at which the unfolded fraction of protein is 0.5) than BSA, indicating that f-BSA has a more stable conformation than BSA. Evidently, intraprotein formaldehyde linkages do retard the conformational transitions of f-BSA, which is consistent with the report by Paliwal et al. that the conformation of the The percentage of aggregates solubility was calculated from the amount of soluble protein recovered in different solvents relative to the total amount of protein aggregates. diphtheria toxoid was stabilized by formalinization and did not undergo a conformational change as easily as diphtheria toxin at acidic pH. 20 
Stabilization of f-BSA Encapsulated in the Polymer
The challenge to formulate stable vaccine antigens in PLGA systems has stimulated considerable interest in the biotechnology and formulation ®elds. Our stabilization approach is to understand the mechanisms of antigen instability in PLGA systems ®rst, instead of or in combination with, traditional trial-and-error methodologies. For f-BSA, we understand that formald-ehydemediated reactivity does initiate aggregation in PLGA (Figures 1 and 2 ; Table 1 ). Combining general instability sources pertaining to PLGA systems with speci®c instability factors for f-BSA, the most important instability sources for encapsulated f-BSA are enumerated as follows: (1) physical and chemical properties intrinsic to formalinized antigens (i.e., formaldehydemediated reactivity); (2) the encapsulation process; and (3) the microsphere environment. As we mentioned before, the deleterious microclimate did not change the aggregation behavior of f-BSA signi®cantly. Thus, in the sections to follow we focused on stabilization strategies targeting the ®rst two aspects.
Enhanced Stability of f-BSA Afforded by the O/O Encapsulation Method
Among the microencapsulation techniques, the w/o/w method is one of the most convenient ways to encapsulate proteins in PLGA microspheres. However, the presence of the aqueous phase may increase the diffusion of protein to the external phase, resulting in the decreased encapsulation ef®ciency, especially when high protein loading is required. Furthermore, proteins in general become more labile when confronting the organic solvent±water interface. 21 Compared with the w/o/w method, negligible water content in the o/o system may signi®cantly increase the encapsulation ef®ciency and protein stability. With less exibility for unfolding, aggregation, and chemical reactions in the solid state, proteins display enhanced stability when dispersed in pure organic solvents.
22,23 Thus, we also developed an o/o method to encapsulate f-BSA and compared the stability of f-BSA in o/o microspheres with those prepared by the w/o/w method.
To achieve higher loading, PLGA 50/50 (iv 0.64 dL/g) was selected to encapsulate model antigens and the theoretical loading of f-BSA was 8% in both o/o and w/o/w encapsulation methods. In the o/o method, the polymer concentration in acetonitrile was 10%, and 98AE4% (n 3) encapsulation ef®ciency was achieved. In the w/o/w method, polymer concentration in methylene chloride was 30% and encapsulation ef®ciency was only 49AE3% (n 3). In Table 2 , the in¯uence of encapsulation methods on f-BSA stability at 97% RH and 378C is shown. In the w/o/w formulation, after 16 days of incubation, only 51AE2% of f-BSA remained soluble in microspheres, whereas 112AE1% of f-BSA remained soluble in microspheres. Excellent stability of f-BSA o/o microspheres suggests that the o/o method is superior to the w/o/w method for antigen stability.
Inhibition of f-BSA Aggregation by Histidine and Trehalose
The second strategy applied targeted the speci®c formaldehyde-mediated reactivity intrinsic to formalinized antigens. It has been shown that formaldehyde-mediated aggregation can be inhibited by (1) blocking nucleophiles and/or reducing electrophiles in protein molecules by chemical modi®cation; 7, 8 (2) adding low MW nucleophiles (amino acids) to compete for the reactive electrophiles in protein molecules; 8 and (3) adding sugar molecules that may inhibit aggregation by several mechanisms. 24 Sorbitol has been shown previously to inhibit the aggregation of lyophilized TT effectively. 7, 24 In addition, histidine was found as the most ef®cient nucleophilic stabilizer (it completely inhibits the aggregation of nonencapsulated f-BSA after 35 days of incubation at 80% RH and 378C). 8 In addition to its high nucleophilicity at neutral pH, the ability to strongly interact with slowly released formaldehyde and form a stable reaction product allows histidine to inhibit the FMAP most effectively. Compared with chemical modi®cation, the second and third strategies are more feasible because the chemically modi®ed formalinized antigens may have altered antigenicity. Therefore, in this study, we decided to coencapsulate histidine and a sugar additive with f-BSA in microspheres and investigate if the inhibition of FMAP will be successful in the polymer device.
Before coencapsulating excipients in microspheres, we needed to identify a sugar that can signi®cantly inhibit the aggregation of f-BSA. A series of sugars, including sucrose, trehalose, sorbitol, mannitol, and dextrose, was tested for their impact on the stability of lyophilized f-BSA. These sugars were co-lyophilized with f-BSA separately as a weight ratio of 1:5 and then protein powders were incubated at 378C and 80% RH. After 14 days of incubation, it was shown that coincorporation of either sorbitol or trehalose was most effective, largely increasing the soluble f-BSA percentage from 9% (without additive) to 30% (with additive) (data not shown). In addition, trehalose has been extensively reported to stabilize protein antigens during both lyophilization and microencapsulation processes. The possible mechanisms include stabilizing dried protein structure by replacing H-bonding sites on the protein previously occupied by water, increasing the glass transition temperature of the formulation, and promoting preferential hydration of the antigen. 25 Thus, trehalose was considered for coincorporation with histidine in the f-BSA-containing microspheres.
Before microsphere preparation, f-BSA was colyophilized with histidine only (the weight ratio of f-BSA to histidine was 5:1) or with both histidine and trehalose (the f-BSA/histidine/trehalose weight ratio was 5:0.5:0.5). Microspheres with 8% f-BSA loading were prepared by the o/o method. In Table 2 , the loss of soluble protein in microspheres with time of incubation at 378C and 80% RH is displayed. Without any stabilizers, f-BSA lost 70% of its solubility after 6 days of incubation, whereas f-BSA coencapsulated with histidine and f-BSA coencapsulated with histidine and trehalose still remained 81 and 102% soluble after 28 days of incubation, respectively. These data strongly suggested that histidine successfully inhibited the FMAP in PLGA systems and the addition of trehalose improved the effectiveness of histidine to stabilize f-BSA in PLGA systems. On the ®rst day, 80% of f-BSA was released and the large burst effect could not be reduced even when the loading was decreased to 5% (data not shown). An additional problem for this formulation was the expected low pH microclimate in PLGA 50/50 microspheres during release. 19 Although acidic pH does not aggravate the FMAP, 8 it may induce peptide-bond hydrolysis and other degradation actions. In addition, most bacterial toxoids are generally unstable below pH 4.5, 6 making it desirable for protein antigens to be released from a neutral microenvironment. Therefore, the ®nal goal of this study was to devise a microsphere formulation which could (1) inhibit the aggregation of f-BSA, (2) release f-BSA continuously, and (3) strongly suppress the acidic microenvironment during f-BSA release.
We have previously reported the use of a PLA/ PEG blend o/o formulation which (1) successfully eliminates the acid-induced noncovalent aggregation and peptide hydrolysis of BSA, and (2) provides a slow and continuous release of BSA for 4 weeks. 26 This formulation is suggested to have a more neutral microclimate than typical PLGA 50/50 microspheres because acid-labile BSA is stable in the PLA/PEG blend system. In addition, strong water uptake of PEG signi®-cantly increases the water content in the blend. Therefore, the PLA/PEG blend formulation with neutral microclimate pH and high water content was utilized to encapsulate f-BSA by the o/o method. As seen in Figure 4 , after preparation microspheres prepared from the PLA/PEG blend had spherical and smooth surfaces. In Figure 5 , the effect of PEG blending and coencapsulation of histidine and trehalose on the release kinetics of f-BSA is displayed. In the absence of additives, 34.5% of f-BSA was released out of the microspheres after 60 days of incubation. The solubility of residual f-BSA remaining in microspheres was analyzed and listed in Table 3 . Most remaining f-BSA formed insoluble aggregates (27% soluble in PBST; 38% formed aggregates). Five percent of f-BSA aggregates were identi®ed as soluble in combined denaturing and reducing solvents, indicating most unreleased f-BSA formed formaldehyde-mediated aggregates. After blending PLA with PEG, both release rate and total releasable amount of f-BSA was increased. After 60 days of incubation, formaldehyde-mediated aggregates formed in microspheres were reduced tò 15%. The FMAP was signi®cantly inhibited likely because of the increased water content in microspheres, which is consistent with our previous ®nding that FMAP is less favorable at high water content. 7, 8 With coencapsulation of histidine and trehalose (the ratio of f-BSA/ histidine/trehalose was 1:0.5:0.5), the FMAP was completely halted. For f-BSA, 93.5% was continuously released out of polymer device and unreleased f-BSA fraction remained soluble in microspheres.
CONCLUSIONS
The model formalinized antigen, f-BSA forms aggregates mainly through the formaldehydemediated aggregation pathway when encapsulated in PLGA microspheres. The coencapsulation of histidine and trehalose and the application of o/ o encapsulation technique signi®cantly inhibited the aggregation of f-BSA in the PLGA system. Finally, 2-month controlled release of f-BSA was attained by using the blend of PLA and PEG polymers. Stabilization and controlled release of f-BSA provides a new avenue for the formulation design of formalinized protein antigens, including TT and DT, and other formalinized vaccine antigens in the pipeline for single-dose vaccine development. Figure 2 , it is highly unlikely that any signi®cant aggregation occurred during our procedure of extracting the protein from the polymer.
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